AU2022313210A1 - Bifunctional compounds for degrading btk with enhanced imid activity - Google Patents

Bifunctional compounds for degrading btk with enhanced imid activity Download PDF

Info

Publication number
AU2022313210A1
AU2022313210A1 AU2022313210A AU2022313210A AU2022313210A1 AU 2022313210 A1 AU2022313210 A1 AU 2022313210A1 AU 2022313210 A AU2022313210 A AU 2022313210A AU 2022313210 A AU2022313210 A AU 2022313210A AU 2022313210 A1 AU2022313210 A1 AU 2022313210A1
Authority
AU
Australia
Prior art keywords
membered
alkyl
heterocycloalkyl
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022313210A
Other languages
English (en)
Inventor
Cristiana Guiducci
Mark NOVISKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nurix Therapeutics Inc
Original Assignee
Nurix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc filed Critical Nurix Therapeutics Inc
Publication of AU2022313210A1 publication Critical patent/AU2022313210A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022313210A 2021-07-23 2022-07-22 Bifunctional compounds for degrading btk with enhanced imid activity Pending AU2022313210A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225401P 2021-07-23 2021-07-23
US63/225,401 2021-07-23
PCT/US2022/038084 WO2023004163A1 (en) 2021-07-23 2022-07-22 Bifunctional compounds for degrading btk with enhanced imid activity

Publications (1)

Publication Number Publication Date
AU2022313210A1 true AU2022313210A1 (en) 2024-02-08

Family

ID=82898772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022313210A Pending AU2022313210A1 (en) 2021-07-23 2022-07-22 Bifunctional compounds for degrading btk with enhanced imid activity

Country Status (10)

Country Link
US (1) US20250017922A1 (https=)
EP (1) EP4373493A1 (https=)
JP (1) JP2024526984A (https=)
KR (1) KR20240039001A (https=)
CN (1) CN118019539A (https=)
AU (1) AU2022313210A1 (https=)
CA (1) CA3226590A1 (https=)
IL (1) IL310269A (https=)
MX (1) MX2024000947A (https=)
WO (1) WO2023004163A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600123B2 (ja) 2018-10-15 2024-12-16 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
WO2020167518A1 (en) 2019-02-13 2020-08-20 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
CN115557933B (zh) * 2021-07-01 2024-08-16 杭州和正医药有限公司 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用
AU2022379494A1 (en) * 2021-10-26 2024-05-30 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
CN120202200A (zh) * 2023-06-01 2025-06-24 标新生物医药科技(上海)有限公司 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
CN121335894A (zh) * 2024-02-04 2026-01-13 上海超阳药业有限公司 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600123B2 (ja) 2018-10-15 2024-12-16 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

Also Published As

Publication number Publication date
CA3226590A1 (en) 2023-01-26
CN118019539A (zh) 2024-05-10
IL310269A (en) 2024-03-01
KR20240039001A (ko) 2024-03-26
EP4373493A1 (en) 2024-05-29
JP2024526984A (ja) 2024-07-19
WO2023004163A1 (en) 2023-01-26
MX2024000947A (es) 2024-04-12
US20250017922A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
US12600732B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US20250017922A1 (en) Bifunctional compounds for degrading btk with enhanced imid activity
US12582722B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US20240336595A1 (en) Bifunctional compounds for degrading btk with diminished imid activity
US8304423B2 (en) Modulators of muscarinic receptors
WO2021091575A1 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US20250002489A1 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
US7786107B2 (en) Modulators of muscarinic receptors
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma